Nursing cornerstone: caring must override fear, judgment, labels (“junkies”, “queers”, etc.).
1980-90s HIV/AIDS = “automatic death certificate” ➜ comparable social fear to early COVID-19.
Influential advocates (e.g., Michael Jackson, Ryan White) + government funding (Pres. Reagan) propelled research.
Ongoing need for research: practice = Research evidence + Nurse expertise + Patient preference.
≈ 1{,}000{,}000 people living with HIV in U.S. (book figure; exact year unspecified).
14\% of PLWH (People Living With HIV) unaware of status → critical surveillance gap.
New U.S. diagnosis every 9.5\text{–}10 minutes.
HIV-1: worldwide, more pathogenic.
HIV-2: West Africa, less pathogenic.
Demographic shift: now higher in Black communities & women; previously mostly white MSM (men who have sex with men).
>50\% of PLWH are \ge 50 years; Viagra/Cialis fuel sexual activity, yet older adults test/use condoms less.
National goal: 90\% reduction in new infections by 2030 (diagnose – treat – prevent – respond).
Required: virus access to bloodstream (sexual fluids, blood, perinatal).
Not spread by air, water, insects, casual contact, dishes, or skin-to-skin.
Highest sexual risk = anal intercourse (tearing of rectal mucosa).
Screening of donated blood/organs now routine (prevented tainted transfusions like Ryan White case).
Virus enters host ➜ seeks \text{CD4} T-cell.
Fusion of viral & cell membranes.
Reverse transcriptase converts viral RNA → DNA.
Integrase inserts viral DNA into host DNA ("messes up DNA synthesis").
Transcription/translation produce viral proteins.
Protease cleaves proteins → mature virions.
Budding → release of new viruses ➜ ↑ viral load.
Key measure: Viral Load (VL) = copies / mL blood.
– Diagnostic & treatment-monitoring tool.
– Goal on therapy: “undetectable = untransmittable” (U = U).
Cocktail = combo of drug classes to block multiple steps:
• Fusion/CCR5 inhibitors
• Reverse-Transcriptase Inhibitors (NRTI, NNRTI)
• Integrase Strand Transfer Inhibitors (INSTI)
• Protease Inhibitors (PI)
Classic drug: AZT / Zidovudine (NRTI); crosses placenta, used perinatally; may suppress WBC ➜ monitor counts.
Other common agents for PrEP (pre-exposure prophylaxis): Truvada, Descovy; \approx 99\% effective when taken daily + other precautions.
Therapy always individualized by infectious-disease specialist; nurses ensure adherence, monitor labs, teach S/E.
Stage | Key Features |
---|---|
1. Acute infection | "Window period" ≈ 2\text{–}4 weeks (up to \approx3 wks) post-exposure until antibodies form. Flu-like: fever, sore throat, lymphadenopathy, diarrhea, headache, fatigue. |
2. Clinical latency / Chronic HIV | VL rises slowly; may stay asymptomatic 10\text{–}15 yrs untreated. Persistent/recurrent fever & diarrhea, weight loss, night sweats, oral/vaginal candidiasis, skin lesions. |
3. AIDS | Diagnostic criteria: \text{CD4} < 200\;\text{cells/mm}^3 AND/OR <14\% total lymphocytes AND ≥1 CDC-defined opportunistic infection (OI) or malignancy. Examples: Kaposi’s sarcoma, Pneumocystis jirovecii pneumonia, TB, CMV, candidiasis, AIDS dementia complex, wasting syndrome. |
Antibody/antigen screens
• ELISA (enzyme-linked immunoassay) ×2.
• Confirm with Western Blot (specific antibodies).
• New 4th-gen Ag/Ab tests shorten window.
Viral Load (PCR) – quantitative RNA copies.
• Used for initial diagnosis & ongoing monitoring.
\text{CD4} T-cell count – immunologic status; <200 ⇒ AIDS.
Routine screening recommended ages 15{-}65, all pregnancies, post-sexual-assault, and annually for high-risk groups.
Primary prevention: abstinence, mutually monogamous relationship, consistent condom use, dental dams, latex gloves for contact play.
Needle-exchange programs, clean equipment, education on safer injection; consider PrEP for high-risk users.
Perinatal: treat mother with AZT, newborn AZT syrup; C-section if VL high; avoid breastfeeding where safe substitutes exist.
Goal: suppress VL to undetectable for ≥6 months ➜ non-transmissible.
For healthcare or sexual exposure.
Steps: immediate washing/flushing; report; baseline labs for both parties; start 3-drug ART ASAP (preferably <2 hrs, max 72 hrs); continue 28 days; follow-up VL & antibody tests.
Hand hygiene, gloves for blood/body fluids, needleless IV systems, engineered sharps protection, never recap needles.
Exposure protocol = institutional algorithm + consented testing.
Mandatory confidential partner notification by trained counselors for HIV, syphilis, gonorrhea, chlamydia (state laws). Nurses obtain names/contact; patient identity not disclosed.
Informed consent required for HIV testing (varies by state); post-test counseling mandatory.
Criminal penalties possible for knowingly transmitting HIV.
HIV affects "mind, body, spirit, soul"; chronic, manageable condition today.
Address stigma, mental health, social determinants (housing, drug use, sex work, poverty).
Interdisciplinary team: nurses, physicians, social workers, case managers, PT/OT/ST, chaplains.
Nursing theorists & Lincoln philosophy: caring, non-judgmental approach, cultural competence.
Infections: PCP/PJP pneumonia, recurrent bacterial pneumonia, TB, CMV, toxoplasmosis, cryptococcal meningitis, candida esophagitis.
Malignancies: Kaposi’s sarcoma, non-Hodgkin lymphoma, invasive cervical cancer.
Others: HIV-associated neurocognitive disorder (HAND), AIDS wasting (severe weight loss & diarrhea), shingles, peripheral neuropathy.
PLWH = People Living With HIV
ART = Antiretroviral Therapy
VL = Viral Load
\text{CD4} / \text{CD8} = T-lymphocyte subsets
OI = Opportunistic Infection
PrEP = Pre-Exposure Prophylaxis
PEP = Post-Exposure Prophylaxis
U = U = Undetectable VL ⇒ Untransmittable
\text{CD4} < 200 cells/mm^3 or <14\% total lymphocytes → AIDS.
PrEP effectiveness: \approx99\% (with adherence).
New U.S. HIV diagnosis every 10 minutes.
14\% unaware of infection.
≥50\% of PLWH now ≥50 years old.
National reduction goal: 90\% fewer new infections by 2030.
HIV has evolved from a stigmatized, fatal epidemic to a chronic, highly manageable infection—provided early diagnosis, comprehensive care, strict adherence to ART, and robust prevention strategies. Nurses play a pivotal role in non-judgmental caring, education, advocacy, and vigilant infection monitoring to sustain progress toward ending the epidemic.